Prophylactic hiv vaccine

The invention relates to mAb based chimeric proteins allowing direct in-vivo targeting of antigens to the dendritic cells. GMP manufacturing of a prophylactic vaccine against HIV is ongoing and first in man is expected to start end of 2018.

Keywords: Infectious diseases, vaccine, HIV, dendritic, DC, antigene targeting
Inventors:
Yves LEVYJacques BANCHEREAU

Reference:

BIO12303-T1

Business Developper
contact
Inserm Transfert
Inserm Transfert
Business Developer

You might also be interested in